𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antibodies to hnRNP core protein A1 in connective tissue diseases

✍ Scribed by Giulia C. B. Astaldi Ricotti; Marco Bestagno; Antonella Cerino; Claudia Negri; Roberto Caporali; Fabio Cobianchi; Matteo Longhi; Carlo Maurizio Montecucco


Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
305 KB
Volume
40
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis


We investigated the specificity of circulating autoantibodies to a heterogeneous nuclear ribonuclear protein A1 (hnRNP Al), obtained by recombinant DNA technique, in different rheumatic diseases: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma, primary Sjogren's syndrome (SS), idiopathic Raynaud (IR), mixed connective tissue disease (MCTD), and healthy donors. All sera were tested by ELISA on hnRNP A1 protein. Positive values were obtained in 22% SLE, 19% scleroderma, 10% IR, 40% ( 2 / 5 ) MCTD, 5% SS, and 50% RA patients. The majority of patients reacted with the aminoterminal part (UP1) of hnRNP Al; however, some RA patients reacted also with the carboxy-terminal part that shows partial homology with keratin. Therefore, hnRNP A1 (UPl) can be considered a target of antinuclear autoimmunity in various rheumatic disorders.


πŸ“œ SIMILAR VOLUMES


The Precipitating Antibody to an Acidic
✍ Shunji Yoshida; Masashi Akizuki; Tsuneyo Mimori; Hajime Yamagat; Shinichi Inada; πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 English βš– 752 KB

The clinical significance of antibodies to the Jo-1 antigen in connective tissue diseases was studied. Clinical diagnoses of 11 patients who had anti-Jo-1 antibody were: polymyositis 8, dermatomyositis 1, and overlap syndrome 2 (polymyositis--systemic lupus erythematosus 1, polymyositis--scleroderma

Antibodies to amyloid A protein in rheum
✍ C. P. J. Maury; A. -M. Teppo πŸ“‚ Article πŸ“… 1988 πŸ› Springer 🌐 English βš– 400 KB

Circulating autoantibodies against amyloid A protein (AA) were demonstrated by enzyme immunoassay in 18/62 patients with rheumatoid arthritis (RA) and in 9/27 patients with systemic lupus erythematosus (SLE). In the subset of RA patients who had developed amyloid, the frequency of antibodies to AA w